SEARCH:   Advanced

Blood, 15 August 2007, Vol. 110, No. 4, pp. 1330-1333. Prepublished online as a Blood First Edition Paper on May 11, 2007; DOI 10.1182/blood-2007-03-081133. This Article Abstract Full Text (PDF) Supplemental Methods, Tables, and Figures All Versions of this Article: blood-2007-03-081133v1 110/4/1330    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Löffler, D. Articles by Horn, F. Search for Related Content PubMed PubMed Citation Articles by Löffler, D. Articles by Horn, F. Related Collections Neoplasia Signal Transduction Gene Expression Brief Reports Chemokines, Cytokines, and Interleukins Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Brief Report Interleukin-6–dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer Dennis Löffler1,5, Katja Brocke-Heidrich1,5, Gabriele Pfeifer1, Claudia Stocsits2, Jörg Hackermüller3, Antje K. Kretzschmar3, Renate Burger4, Martin Gramatzki4, Conny Blumert1, Kay Bauer1,5, Helena Cvijic1, A. Kerstin Ullmann1, Peter F. Stadler2,3, and Friedemann Horn1,3,5 1 Institute of Clinical Immunology and Transfusion Medicine, Medical Faculty, University of Leipzig, Leipzig; 2 Bioinformatics Group, Department of Computer Science, University of Leipzig, Leipzig; 3 Fraunhofer Institute of Cell Therapy and Immunology, Leipzig; 4 Division of Stem Cell Transplantation and Immunotherapy, 2nd Medical Department, University Hospital Schleswig-Holstein Campus Kiel, Kiel; 5 Interdisciplinary Center for Clinical Studies, University of Leipzig, Germany    Abstract Top Abstract Introduction Materials and methods Results and discussion Authorship References   Signal transducer and activator of transcription 3 (Stat3) is implicated in the pathogenesis of many malignancies and essential for IL-6–dependent survival and growth of multiple myeloma cells. Here, we demonstrate that the gene encoding oncogenic microRNA-21 (miR-21) is controlled by an upstream enhancer containing 2 Stat3 binding sites strictly conserved since the first observed evolutionary appearance of miR-21 and Stat3. MiR-21 induction by IL-6 was strictly Stat3 dependent. Ectopically raising miR-21 expression in myeloma cells in the absence of IL-6 significantly reduced their apoptosis levels. These data provide strong evidence that miR-21 induction contributes to the oncogenic potential of Stat3.    Introduction Top Abstract Introduction Materials and methods Results and discussion Authorship References   Signal transducer and activator of transcription 3 (Stat3), the major mediator of IL-6 signaling,1,2 participates in cellular transformation and oncogenesis.3,4 Its activation is essential for the transforming potential of many oncogenes. Previously, we could show that Stat3 activation is required for IL-6–dependent growth and survival of the human myeloma cell lines INA-6 and XG-1.5 Although microarray analyses revealed that in these cells the vast majority of IL-6 target genes is controlled through Stat3, differential expression of known apoptosis regulators (eg, members of the Bcl-2 family) could not sufficiently account for the observed Stat3-mediated survival effect.5 We therefore searched for additional mechanisms through which Stat3 may suppress apoptosis in cancer cells. MicroRNAs (miRNAs) are an abundant class of short non-protein-coding RNAs (ncRNAs) mediating posttranscriptional down-regulation of target genes. They have been shown to play a fundamental role in diverse physiologic and pathologic processes, including proliferation, apoptosis, differentiation, and cell fate determination.6,7 Recent evidence indicates that miRNAs can function as tumor suppressors and oncogenes.8 Hence, we reasoned that miRNAs might be implicated in the Stat3-mediated survival of myeloma cells.    Materials and methods Top Abstract Introduction Materials and methods Results and discussion Authorship References   A detailed description of the bioinformatic procedures and the vectors and primer sequences used is given in Document S1 (available on the Blood website; see the Supplemental Materials link at the top of the online article). INA-6 and XG-1 myeloma and HepG2 hepatocellular carcinoma cells were cultivated, and reporter gene assays were performed as recently described.5,9 Chromatin immunoprecipitation was performed using a kit (EZ ChIP) from Upstate (Lake Placid, NY) according to the manufacturer's instructions. Coimmunoprecipitated DNA was amplified using primers specific for the miR-21 upstream region and analyzed on an agarose gel. Anti-Stat3 serum (PA-ST3) was from R&D Systems (Wiesbaden, Germany). RNA interference knock-down of Stat3 and overexpression of miR-21 in myeloma cells was performed by electroporation with pSUPER vectors as described.9 In short, 1 µg green fluorescent protein expression vector pEGFP-N1 (Clontech, Mountain View, CA) and 19 µg expression vectors encoding either a small hairpin RNA targeting Stat3 mRNA (pSUPER-siStat3)9 or precursor miR-21 (pSUPER-miR-21), or a pSUPER control vector were electroporated into 5 x 106 cells. For each experiment, 3 x 107 cells were combined and successfully transfected, and green fluorescent cells were sorted 48 hours after transfection using a FACS-Vantage Sorter (BD Biosciences, Heidelberg, Germany). For real-time polymerase chain reaction (PCR) of Stat3 mRNA and primary miR-21 transcripts (pri-miR-21), total RNA was prepared using the mirVana miRNA Isolation Kit (Ambion, Austin, TX) and quantified by the RNA 6000 LabChip Kit (2100 Bioanalyzer; Agilent Technologies, Waldbronn, Germany). Reverse transcription was done with the SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen, Karlsruhe, Germany). Real-time PCR was performed using a LightCycler (Roche, Mannheim, Germany). An optimal PCR reaction was established with the FastStart DNA Master SYBR Green I Kit (Roche), and it was taken care that only 1 PCR product was generated. Specificity of amplification was validated by confirming the identity of PCR products by sequencing. Mature miR-21 was detected by stem-loop reverse transcription followed by real-time PCR.10 Signals were normalized to values obtained for glyceraldehyde-3-phosphate dehydrogenase. Apoptosis was detected by flow cytometry using annexin-V staining as previously described.5    Results and discussion Top Abstract Introduction Materials and methods Results and discussion Authorship References   To investigate whether Stat3 is involved in the regulation of miRNA genes, we analyzed the genomic distribution of Stat3 binding sites and their correlation with known miRNAs by phylogenetic footprinting (for details, see Document S1). Among the miRNA genes associated with evolutionarily conserved putative Stat3 binding sites, miR-21 has been described as an oncogenic miRNA exhibiting antiapoptotic activity in various carcinomas.11–13 The putative regulatory region of the miR-21 gene is located within an intron of the overlapping transmembrane protein 49 (TMEM49) gene, and contains 2 consensus Stat3 binding sites approximately 800 bp upstream of the transcription start site. It is evident from Figure 1A that the Stat3 sites and the surrounding region, spanning 300 bp, are highly conserved in vertebrates at least since the common ancestor of tetrapods and actinopterygian fish (ie, since the first evolutionary appearance of miR-21 and Stat3 in species for which genome-wide data are available). View larger version (55K): [in this window] [in a new window]   Figure 1. A highly conserved enhancer is responsible for the Stat3-mediated responsiveness of the miR-21 promoter to IL-6. (A) 130-bp regions containing 2 predicted Stat3 binding sites upstream of the miR-21 genes of various vertebrate species are aligned. T, G, C, and A nucleotides are colored green, orange, blue, and red, respectively. Stat3 sites are highlighted by yellow boxes. *Sequences from organisms where no genomic sequence was available were obtained from the Ensembl trace repository (Table S2). (B) XG-1 cells were deprived of IL-6 for 72 hours or restimulated for 30 minutes and subjected to a chromatin immunoprecipitation (ChIP) assay using anti-Stat3 or IgG isotype control. Coimmunoprecipitated DNA was amplified by PCR with primers specific for the miR-21 upstream enhancer. (C) Reporter gene assays were performed in HepG2 cells transfected either with a luciferase vector driven by the miR-21 promoter/enhancer alone (–) or in the presence of a vector encoding a small hairpin RNA silencing Stat3 expression (siStat3), or with a miR-21 promoter/enhancer construct containing point mutations in both Stat3 sites (Stat3). Values represent the mean luciferase activities ± SD of 3 independent experiments relative to samples from unmanipulated IL-6–treated cells.   Genomic data suggest that miR-21 and its associated Stat3 binding sites are functionally independent of TMEM49 (Table S1). A stable distance between miR-21 and the Stat3 sites throughout all vertebrates strongly suggests their functional correlation (Figure S1). Chromatin immunoprecipitation revealed that Stat3 is indeed recruited to the miR-21 upstream region in XG-1 human myeloma cells in response to IL-6 (Figure 1B). Furthermore, a genomic DNA fragment extending from –1120 to +25 bp relative to the miR-21 transcription start site14 and containing the putative Stat3 enhancer region proved to be IL-6–responsive in a reporter assay (Figure 1C). IL-6–induced miR-21 promoter activity was abolished when the Stat3 motifs were eliminated by site-directed mutagenesis. Likewise, knocking down Stat3 by RNA interference inhibited miR-21 promoter activity. The effects of Stat3 knockdown could be rescued by expression of an siRNA-resistant variant of Stat3 (Figure S2). These data demonstrate the existence of a functional Stat3-regulated enhancer upstream of the miR-21 gene, as predicted by the bioinformatic analysis. To verify that IL-6 induces the transcription of the miR-21 gene, pri-miR-21 and mature miR-21 were quantified by real-time PCR in XG-1 and INA-6 myeloma cells. IL-6 increased pri-miR-21 expression substantially in either cell line (Figure 2A). Upon Stat3 knockdown, comparable reductions of Stat3 mRNA and pri-miR-21 levels were observed (Figure 2B), proving that miR-21 induction by IL-6 is mediated by Stat3. Induction of miR-21 expression by IL-6 is not restricted to multiple myeloma, as it is observed in other tumor cell lines as well (Figure S3). Taken together, our data demonstrate that miR-21 gene transcription is controlled by IL-6 and requires Stat3. In contrast to the rapid induction of pri-miR-21, mature miR-21 levels raised slowly in XG-1 cells, eventually reaching a 4-fold increase (Figure 2C). The same was observed in prostate carcinoma cells (Figure S3), indicating a rather slow processing rate of pri-miR-21. View larger version (27K): [in this window] [in a new window]   Figure 2. miR-21 is induced by IL-6 via Stat3 activation and promotes survival of myeloma cells. (A) XG-1 and INA-6 cells were either restimulated with IL-6 for the times indicated after cytokine withdrawal for 72 and 12 hours, respectively, or continuously cultured with IL-6 (perm.). Levels of pri-miR-21 were determined by real-time PCR. Values obtained for cells deprived of IL-6 were set to 1. (B) XG-1 and INA-6 cells cultured in the presence of IL-6 were transiently transfected with an expression plasmid for a small hairpin RNA-silencing Stat3 () or a scrambled sequence RNA () together with a vector-encoding enhanced GFP. Successful down-regulation of Stat3 protein levels under these conditions has been demonstrated by us previously.9 After 48 hours, green fluorescent cells were sorted, and Stat3 and pri-miR-21 transcript levels were determined by real-time PCR. Values for the control samples were taken as reference. (C) In XG-1 cells treated as were INA-6 cells, mature miR-21 was quantified by stem-loop reverse transcription followed by real-time PCR.10 (D,E) INA-6 cells were transiently transfected by electroporation with a control (D) or a miR-21 expression vector (E). An expression plasmid encoding enhanced GFP was cotransfected. At 1 day after transfection, cell culture was continued either in the presence or absence of IL-6. After an additional 24 or 48 hours, apoptosis was studied by flow cytometric annexin-V assay, with the transfected cells gated on the basis of green fluorescence. In panel D, the reduced levels of viable (annexin-V–) cells after cytokine withdrawal are represented relative to those observed in IL-6–treated cells. Panel E shows the relative percentage of viable cells with miR-21 expression vector relative to control vector transfection. Data represent mean values plus or minus SD from 3 independent experiments.   Since miR-21 is involved in the control of tumor cell apoptosis,11–13 we reasoned that it might contribute to the Stat3-dependent survival of myeloma cells. Due to relatively high basal miR-21 expression levels, a miR-21 knockdown might cause effects that go beyond Stat3 regulation. Therefore, we chose to ectopically elevate miR-21 expression in the absence of IL-6 to levels comparable with those observed in response to Stat3 activation. Upon electroporation of INA-6 cells with a miR-21 expression vector and sorting of the transfected cells, we determined a 2.4-fold increase in mature miR-21 expression over endogenous levels by real-time PCR analysis (mean of 3 independent experiments). As reported earlier,5 IL-6 withdrawal rapidly induced apoptosis in INA-6 cells (Figure 2D). Raising miR-21 expression, however, yielded significantly higher levels of nonapoptotic cells (Figure 2E). This effect was most dramatic in the absence of IL-6, reducing the cytokine dependency of the INA-6 cells. Equivalent observations were made in XG-1 cells (data not shown). In summary, these data provide strong evidence that induction of miR-21 contributes to the antiapoptotic function of Stat3. Stat3 controls the expression of a number of antiapoptotic proteins on the transcriptional level, including survivin, Bcl-2, and Mcl-1,15–18 thereby providing an important fast-track survival signal for myeloma and presumably other tumor cells. However, recent data suggest that this regulatory route does not sufficiently explain the full antiapoptotic potential of Stat3.5,19 As demonstrated here, miR-21 induction by Stat3 represents a rather slow-acting yet long-lasting survival stimulus, which appears as an ideal complementation of the immediate induction of antiapoptotic proteins. Overexpression of miR-21 has been reported for numerous cancers,11,20,21 all of which contain constitutively activated Stat3 or even rely on Stat3 with respect to cell survival or growth.11,12,15,16,22 Taken together, our observations strongly suggest a pivotal relevance of miR-21 for the oncogenic potential of Stat3 and thereby for its involvement in the pathogenesis of multiple myeloma and other malignancies. Since miRNAs function as negative regulators of the stability and/or translation of specific target mRNAs, an important step to unravel the molecular mechanism of miR-21 action will be to identify its mRNA targets. Recently, miR-21 was reported to repress the expression of the tumor suppressor PTEN.12 Yet, we did not detect up-regulation of PTEN expression or AKT phosphorylation in INA-6 and XG-1 cells in response to IL-6 (data not shown). Stat3 is regarded a promising target for tumor therapy.23–25 However, its involvement in the control of numerous cellular processes may cause adverse side effects of such treatments. The identification of miR-21 as a Stat3 target gene may provide an even more selective and promising target for future therapeutic strategies.    Authorship Top Abstract Introduction Materials and methods Results and discussion Authorship References   Contribution: F.H., K.B.-H., J.H., A.K.K., M.G., and P.F.S designed research; D.L., K.B.-H., G.P., C.F., C.B., K.B., and H.C. performed research; R.B. and M.G. contributed vital new reagents or analytical tools; A.K.U. analyzed data; and F.H., K.B.-H., and P.F.S wrote the paper. D.L. and K.B.-H. contributed equally to this work. Conflict-of-interest disclosure: The authors declare no competing financial interests. Correspondence: Friedemann Horn, Institute of Clinical Immunology and Transfusion Medicine, University of Leipzig, Johannisallee 30, 04103 Leipzig, Germany; e-mail: friedemann.horn{at}medizin.uni-leipzig.de.    Acknowledgments   We thank Stefan Rose-John (University of Kiel) for recombinant IL-6, Reuven Agami (The Netherlands Cancer Institute, Amsterdam) for the pSuper vector, and Viola Döbel (Fluorescence Technologies Core Unit of the IZKF Leipzig) for cell sorting. This work was supported in part by the Deutsche Forschungsgemeinschaft, grant nos. SFB610, project C2 (to D.L., C.B., H.C., and F.H.) and BIZ 6-1/3 (to C.F and P.F.S).    Footnotes   Submitted March 21, 2007; accepted April 27, 2007. Prepublished online as Blood First Edition Paper, May 11, 2007 DOI: 10.1182/blood-2007-03-081133 An Inside Blood analysis of this article appears at the front of this issue. The online version of this article contains a data supplement. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.    References Top Abstract Introduction Materials and methods Results and discussion Authorship References   Wegenka UM, Buschmann J, Lütticken C, Heinrich PC, Horn F. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol 1993; 13:276–288.[Abstract/Free Full Text] Lütticken C, Wegenka UM, Yuan J, et al. Association of transcription factor APRF and protein kinase JAK1 with the IL-6 signal transducer gp130. Science 1994; 263:89–92.[Abstract/Free Full Text] Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999; 98:295–303.[CrossRef][Medline] [Order article via Infotrieve] Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005; 41:2502–2512.[CrossRef][Medline] [Order article via Infotrieve] Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, et al. Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood 2004; 103:242–251.[Abstract/Free Full Text] Hwang HW and Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 2006; 94:776–780.[CrossRef][Medline] [Order article via Infotrieve] Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004; 303:83–86.[Abstract/Free Full Text] Esquela-Kerscher A and Slack FJ. Oncomirs: microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259–269.[CrossRef][Medline] [Order article via Infotrieve] Brocke-Heidrich K, Ge B, Cvijic H, et al. BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. Oncogene 2006; 25:7297–7304.[CrossRef][Medline] [Order article via Infotrieve] Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33:e179.[Abstract/Free Full Text] Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65:6029–6033.[Abstract/Free Full Text] Meng F, Henson R, Lang M, et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 2006; 130:2113–2129.[CrossRef][Medline] [Order article via Infotrieve] Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2007; 282:14328–14336. Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 2004; 10:1957–1966.[Abstract/Free Full Text] Isomoto H, Kobayashi S, Werneburg NW, et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005; 42:1329–1338.[CrossRef][Medline] [Order article via Infotrieve] Konnikova L, Kotecki M, Kruger MM, Cochran BH. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 2003; 3:23.[CrossRef][Medline] [Order article via Infotrieve] Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003; 101:1535–1542.[Abstract/Free Full Text] Jourdan M, Veyrune JL, Vos JD, Redal N, Couderc G, Klein B. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 2003; 22:2950–2959.[CrossRef][Medline] [Order article via Infotrieve] Tumang JR, Hsia CY, Tian W, Bromberg JF, Liou HC. IL-6 rescues the hyporesponsiveness of c-Rel deficient B cells independent of Bcl-xL, Mcl-1, and Bcl-2. Cell Immunol 2002; 217:47–57.[CrossRef][Medline] [Order article via Infotrieve] Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006; 103:2257–2261.[Abstract/Free Full Text] Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65:7065–7070.[Abstract/Free Full Text] Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 2002; 21:8404–8413.[CrossRef][Medline] [Order article via Infotrieve] Klampfer L. Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Targets 2006; 6:107–121.[CrossRef][Medline] [Order article via Infotrieve] Haura EB, Turkson J, Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Pract Oncol 2005; 2:315–324.[CrossRef][Medline] [Order article via Infotrieve] Secko D. Cancer therapy finds a solid target. CMAJ 2005; 173:246.[Free Full Text] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: The STATus of miR-21 in apoptosis Elaine M. Hurt and William L. Farrar Blood 2007 110: 1086-1087. [Full Text] [PDF] This article has been cited by other articles: M. V. Iorio and C. M. Croce MicroRNAs in Cancer: Small Molecules With a Huge Impact J. Clin. Oncol., December 1, 2009; 27(34): 5848 - 5856. [Abstract] [Full Text] [PDF] G. A. Calin and C. M. Croce Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes Blood, November 26, 2009; 114(23): 4761 - 4770. [Abstract] [Full Text] [PDF] E. A. Mathe, G. H. Nguyen, E. D. Bowman, Y. Zhao, A. Budhu, A. J. Schetter, R. Braun, M. Reimers, K. Kumamoto, D. Hughes, et al. MicroRNA Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus: Associations with Survival Clin. Cancer Res., October 1, 2009; 15(19): 6192 - 6200. [Abstract] [Full Text] [PDF] J. Ribas, X. Ni, M. Haffner, E. A. Wentzel, A. H. Salmasi, W. H. Chowdhury, T. A. Kudrolli, S. Yegnasubramanian, J. Luo, R. Rodriguez, et al. miR-21: An Androgen Receptor-Regulated MicroRNA that Promotes Hormone-Dependent and Hormone-Independent Prostate Cancer Growth Cancer Res., September 15, 2009; 69(18): 7165 - 7169. [Abstract] [Full Text] [PDF] A. J. Schetter, G. H. Nguyen, E. D. Bowman, E. A. Mathe, S. T. Yuen, J. E. Hawkes, C. M. Croce, S. Y. Leung, and C. C. Harris Association of Inflammation-Related and microRNA Gene Expression with Cancer-Specific Mortality of Colon Adenocarcinoma Clin. Cancer Res., September 15, 2009; 15(18): 5878 - 5887. [Abstract] [Full Text] [PDF] G. Sotiropoulou, G. Pampalakis, E. Lianidou, and Z. Mourelatos Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell RNA, August 1, 2009; 15(8): 1443 - 1461. [Abstract] [Full Text] [PDF] M. Seike, A. Goto, T. Okano, E. D. Bowman, A. J. Schetter, I. Horikawa, E. A. Mathe, J. Jen, P. Yang, H. Sugimura, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers PNAS, July 21, 2009; 106(29): 12085 - 12090. [Abstract] [Full Text] [PDF] T.-H. Huang, F. Wu, G. B. Loeb, R. Hsu, A. Heidersbach, A. Brincat, D. Horiuchi, R. J. Lebbink, Y.-Y. Mo, A. Goga, et al. Up-regulation of miR-21 by HER2/neu Signaling Promotes Cell Invasion J. Biol. Chem., July 3, 2009; 284(27): 18515 - 18524. [Abstract] [Full Text] [PDF] N. Yamamichi, R. Shimomura, K.-i. Inada, K. Sakurai, T. Haraguchi, Y. Ozaki, S. Fujita, T. Mizutani, C. Furukawa, M. Fujishiro, et al. Locked Nucleic Acid In situ Hybridization Analysis of miR-21 Expression during Colorectal Cancer Development Clin. Cancer Res., June 15, 2009; 15(12): 4009 - 4016. [Abstract] [Full Text] [PDF] M. Brock, M. Trenkmann, R. E. Gay, B. A. Michel, S. Gay, M. Fischler, S. Ulrich, R. Speich, and L. C. Huber Interleukin-6 Modulates the Expression of the Bone Morphogenic Protein Receptor Type II Through a Novel STAT3-microRNA Cluster 17/92 Pathway Circ. Res., May 22, 2009; 104(10): 1184 - 1191. [Abstract] [Full Text] [PDF] C. S. Velu, A. M. Baktula, and H. L. Grimes Gfi1 regulates miR-21 and miR-196b to control myelopoiesis Blood, May 7, 2009; 113(19): 4720 - 4728. [Abstract] [Full Text] [PDF] V. Jayaswal, M. Lutherborrow, D. D. F. Ma, and Y. Hwa Yang Identification of microRNAs with regulatory potential using a matched microRNA-mRNA time-course data Nucleic Acids Res., May 1, 2009; 37(8): e60 - e60. [Abstract] [Full Text] [PDF] T. X. Lu, A. Munitz, and M. E. Rothenberg MicroRNA-21 Is Up-Regulated in Allergic Airway Inflammation and Regulates IL-12p35 Expression J. Immunol., April 15, 2009; 182(8): 4994 - 5002. [Abstract] [Full Text] [PDF] M. Z. Carletti and L. K. Christenson MicroRNA in the ovary and female reproductive tract J Anim Sci, April 1, 2009; 87(14_suppl): E29 - E38. [Abstract] [Full Text] [PDF] F J Sheedy and L A J O'Neill Adding fuel to fire: microRNAs as a new class of mediators of inflammation Ann Rheum Dis, December 1, 2008; 67(Suppl_3): iii50 - iii55. [Abstract] [Full Text] [PDF] F. Ozsolak, L. L. Poling, Z. Wang, H. Liu, X. S. Liu, R. G. Roeder, X. Zhang, J. S. Song, and D. E. Fisher Chromatin structure analyses identify miRNA promoters Genes & Dev., November 15, 2008; 22(22): 3172 - 3183. [Abstract] [Full Text] [PDF] F. Pichiorri, S.-S. Suh, M. Ladetto, M. Kuehl, T. Palumbo, D. Drandi, C. Taccioli, N. Zanesi, H. Alder, J. P. Hagan, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis PNAS, September 2, 2008; 105(35): 12885 - 12890. [Abstract] [Full Text] [PDF] G. Gabriely, T. Wurdinger, S. Kesari, C. C. Esau, J. Burchard, P. S. Linsley, and A. M. Krichevsky MicroRNA 21 Promotes Glioma Invasion by Targeting Matrix Metalloproteinase Regulators Mol. Cell. Biol., September 1, 2008; 28(17): 5369 - 5380. [Abstract] [Full Text] [PDF] E. Connolly, M. Melegari, P. Landgraf, T. Tchaikovskaya, B. C. Tennant, B. L. Slagle, L. E. Rogler, M. Zavolan, T. Tuschl, and C. E. Rogler Elevated Expression of the miR-17-92 Polycistron and miR-21 in Hepadnavirus-Associated Hepatocellular Carcinoma Contributes to the Malignant Phenotype Am. J. Pathol., September 1, 2008; 173(3): 856 - 864. [Abstract] [Full Text] [PDF] S.-J. Hu, G. Ren, J.-L. Liu, Z.-A. Zhao, Y.-S. Yu, R.-W. Su, X.-H. Ma, H. Ni, W. Lei, and Z.-M. Yang MicroRNA Expression and Regulation in Mouse Uterus during Embryo Implantation J. Biol. Chem., August 22, 2008; 283(34): 23473 - 23484. [Abstract] [Full Text] [PDF] D. Sayed, S. Rane, J. Lypowy, M. He, I.-Y. Chen, H. Vashistha, L. Yan, A. Malhotra, D. Vatner, and M. Abdellatif MicroRNA-21 Targets Sprouty2 and Promotes Cellular Outgrowths Mol. Biol. Cell, August 1, 2008; 19(8): 3272 - 3282. [Abstract] [Full Text] [PDF] D. G. Romero, M. W. Plonczynski, C. A. Carvajal, E. P. Gomez-Sanchez, and C. E. Gomez-Sanchez Microribonucleic Acid-21 Increases Aldosterone Secretion and Proliferation in H295R Human Adrenocortical Cells Endocrinology, May 1, 2008; 149(5): 2477 - 2483. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Supplemental Methods, Tables, and Figures All Versions of this Article: blood-2007-03-081133v1 110/4/1330    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Löffler, D. Articles by Horn, F. Search for Related Content PubMed PubMed Citation Articles by Löffler, D. Articles by Horn, F. Related Collections Neoplasia Signal Transduction Gene Expression Brief Reports Chemokines, Cytokines, and Interleukins Related Article in Blood Online Social Bookmarking                   What's this?

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020